360 related articles for article (PubMed ID: 19887776)
1. Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry.
Kim SJ; Kim K; Kim BS; Jo DY; Kang HJ; Kim JS; Mun YC; Kim CS; Sohn SK; Eom HS; Kwak JY; Shim H; Yoon HJ; Jin JY; Min CK; Shin H; Won JH; Lee JJ; Kwon JH; Joo YD; Do YR; Kim SH; Oh S; Suh C; Lee J; Yoon SS; Kim MK; Bang SM; Ryoo HM; Kim BS; Kim H; Kim HJ; Kim YS; Park CW; Lee GW; Shin HJ; Park SK; Park JS; Kim HY; Lee DS; Lee JH;
Acta Haematol; 2009; 122(4):200-10. PubMed ID: 19887776
[TBL] [Abstract][Full Text] [Related]
2. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
3. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
Lahuerta JJ; Mateos MV; Martínez-López J; Rosiñol L; Sureda A; de la Rubia J; García-Laraña J; Martínez-Martínez R; Hernández-García MT; Carrera D; Besalduch J; de Arriba F; Ribera JM; Escoda L; Hernández-Ruiz B; García-Frade J; Rivas-González C; Alegre A; Bladé J; San Miguel JF
J Clin Oncol; 2008 Dec; 26(35):5775-82. PubMed ID: 19001321
[TBL] [Abstract][Full Text] [Related]
4. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
Cheema PK; Zadeh S; Kukreti V; Reece D; Chen C; Trudel S; Mikhael J
Biol Blood Marrow Transplant; 2009 Jun; 15(6):686-93. PubMed ID: 19450753
[TBL] [Abstract][Full Text] [Related]
5. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
6. Impact of early relapse after auto-SCT for multiple myeloma.
Kumar S; Mahmood ST; Lacy MQ; Dispenzieri A; Hayman SR; Buadi FK; Dingli D; Rajkumar SV; Litzow MR; Gertz MA
Bone Marrow Transplant; 2008 Sep; 42(6):413-20. PubMed ID: 18587435
[TBL] [Abstract][Full Text] [Related]
7. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.
Qazilbash MH; Saliba RM; Ahmed B; Parikh G; Mendoza F; Ashraf N; Hosing C; Flosser T; Weber DM; Wang M; Couriel DR; Popat U; Kebriaei P; Alousi AM; Anderlini P; Naeem RC; Champlin RE; Giralt SA
Biol Blood Marrow Transplant; 2007 Sep; 13(9):1066-72. PubMed ID: 17697969
[TBL] [Abstract][Full Text] [Related]
8. Autologous stem cell transplantation in multiple myeloma patients <60 vs >/=60 years of age.
Reece DE; Bredeson C; Pérez WS; Jagannath S; Zhang MJ; Ballen KK; Elfenbein GJ; Freytes CO; Gale RP; Gertz MA; Gibson J; Giralt SA; Keating A; Kyle RA; Maharaj D; Marcellus D; McCarthy PL; Milone GA; Nimer SD; Pavlovsky S; To LB; Weisdorf DJ; Wiernik PH; Wingard JR; Vesole DH
Bone Marrow Transplant; 2003 Dec; 32(12):1135-43. PubMed ID: 14647267
[TBL] [Abstract][Full Text] [Related]
9. Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study.
Morris C; Iacobelli S; Brand R; Bjorkstrand B; Drake M; Niederwieser D; Gahrton G;
J Clin Oncol; 2004 May; 22(9):1674-81. PubMed ID: 15037597
[TBL] [Abstract][Full Text] [Related]
10. Simple variables predict survival after autologous transplantation: a single centre experience in 181 multiple myeloma patients.
Krejci M; Hajek R; Buchler T; Krivanova A; Svobodnik A; Pour L; Adam Z; Mayer J; Vorlicek J
Neoplasma; 2007; 54(2):143-8. PubMed ID: 17319788
[TBL] [Abstract][Full Text] [Related]
11. Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders.
Kumar SK; Dingli D; Lacy MQ; Dispenzieri A; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
Br J Haematol; 2008 Apr; 141(2):205-11. PubMed ID: 18318761
[TBL] [Abstract][Full Text] [Related]
12. Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma.
Kim H; Sohn HJ; Kim S; Lee JS; Kim WK; Suh C
Bone Marrow Transplant; 2006 Jun; 37(11):1037-42. PubMed ID: 16708062
[TBL] [Abstract][Full Text] [Related]
13. Impact of MiRSNPs on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation.
de Larrea CF; Navarro A; Tejero R; Tovar N; Díaz T; Cibeira MT; Rosiñol L; Ferrer G; Rovira M; Rozman M; Monzó M; Bladé J
Clin Cancer Res; 2012 Jul; 18(13):3697-704. PubMed ID: 22539802
[TBL] [Abstract][Full Text] [Related]
14. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis.
Kumar SK; Dingli D; Lacy MQ; Dispenzieri A; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
Am J Hematol; 2008 Aug; 83(8):614-7. PubMed ID: 18429054
[TBL] [Abstract][Full Text] [Related]
15. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
Oh S; Koo DH; Kwon MJ; Kim K; Suh C; Min CK; Yoon SS; Shin HJ; Jo DY; Kwak JY; Kim JS; Sohn SK; Joo YD; Eom HS; Kim SH; Kim YS; Kim C; Mun YC; Kim H; Lee DS; Lee JH;
Ann Hematol; 2014 Aug; 93(8):1353-61. PubMed ID: 24671365
[TBL] [Abstract][Full Text] [Related]
16. Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE.
Srikanth M; Davies FE; Wu P; Jenner MW; Ethell ME; Potter MN; Shaw BE; Saso RM; Dines S; Morgan GJ
Eur J Haematol; 2008 Dec; 81(6):432-6. PubMed ID: 18691254
[TBL] [Abstract][Full Text] [Related]
17. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.
Terpos E; Katodritou E; Roussou M; Pouli A; Michalis E; Delimpasi S; Parcharidou A; Kartasis Z; Zomas A; Symeonidis A; Viniou NA; Anagnostopoulos N; Economopoulos T; Zervas K; Dimopoulos MA;
Eur J Haematol; 2010 Aug; 85(2):114-9. PubMed ID: 20477863
[TBL] [Abstract][Full Text] [Related]
18. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N
J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705
[TBL] [Abstract][Full Text] [Related]
19. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome.
Minnema MC; van de Donk NW; Zweegman S; Hegenbart U; Schonland S; Raymakers R; Zijlmans JM; Kersten MJ; Bos GM; Lokhorst HM
Bone Marrow Transplant; 2008 May; 41(9):779-84. PubMed ID: 18195681
[TBL] [Abstract][Full Text] [Related]
20. Survival of myeloma patients following the introduction of thalidomide as a second-line therapy: a retrospective study at a single New Zealand centre.
Fernyhough LJ; Hock BD; Taylor J; Pearson J; Ganly P
Intern Med J; 2013 Feb; 43(2):130-7. PubMed ID: 22530659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
